Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer

Conclusions
Our data suggest siPLK1-StAv-SPIONs with dual specificity residues for tumour targeting and membrane translocation to represent an exciting opportunity for targeted therapy in patients with PDAC.

Source: Gut - October 6, 2016 Category: Gastroenterology Authors: Mahajan, U. M., Teller, S., Sendler, M., Palankar, R., van den Brandt, C., Schwaiger, T., Kühn, J.-P., Ribback, S., Glöckl, G., Evert, M., Weitschies, W., Hosten, N., Dombrowski, F., Delcea, M., Weiss, F.-U., Lerch, M. M., Mayerle, J. Tags: Pancreas and biliary tract, Open access, Pancreatic cancer Source Type: research